JP2013538566A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538566A5
JP2013538566A5 JP2013523643A JP2013523643A JP2013538566A5 JP 2013538566 A5 JP2013538566 A5 JP 2013538566A5 JP 2013523643 A JP2013523643 A JP 2013523643A JP 2013523643 A JP2013523643 A JP 2013523643A JP 2013538566 A5 JP2013538566 A5 JP 2013538566A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
dom7h
acid sequence
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013523643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/063999 external-priority patent/WO2012020143A1/en
Publication of JP2013538566A publication Critical patent/JP2013538566A/ja
Publication of JP2013538566A5 publication Critical patent/JP2013538566A5/ja
Pending legal-status Critical Current

Links

JP2013523643A 2010-08-13 2011-08-12 改良された抗血清アルブミン結合変異体 Pending JP2013538566A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37339710P 2010-08-13 2010-08-13
US61/373,397 2010-08-13
PCT/EP2011/063999 WO2012020143A1 (en) 2010-08-13 2011-08-12 Improved anti-serum albumin binding variants

Publications (2)

Publication Number Publication Date
JP2013538566A JP2013538566A (ja) 2013-10-17
JP2013538566A5 true JP2013538566A5 (enExample) 2014-09-18

Family

ID=44582954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013523643A Pending JP2013538566A (ja) 2010-08-13 2011-08-12 改良された抗血清アルブミン結合変異体

Country Status (4)

Country Link
US (2) US9012609B2 (enExample)
EP (1) EP2603522A1 (enExample)
JP (1) JP2013538566A (enExample)
WO (1) WO2012020143A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
EP2603522A1 (en) * 2010-08-13 2013-06-19 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
US20160222087A1 (en) * 2013-09-13 2016-08-04 Novozymes Biopharma Dk A/S Albumin variants
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
HUE057241T2 (hu) * 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
WO2018104444A1 (en) * 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
EP4442709A3 (en) 2017-01-17 2024-12-25 Ablynx NV Improved serum albumin binders
PT3583125T (pt) 2017-02-16 2025-04-04 Sonnet Biotherapeutics Inc Proteínas de fusão ao domínio de ligação à albumina
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658739A (en) 1994-05-10 1997-08-19 The Regents Of The University Of California Method for characterization of the fine structure of protein binding sites
US6291189B1 (en) 1994-05-10 2001-09-18 Carta Proteomics, Inc. Methods for the high-resolution identification of solvent-accessible amide hydrogens in polypeptides or proteins and for characterization of the fine structure of protein binding sites
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
WO2004035751A2 (en) 2002-10-18 2004-04-29 The Regents Of The University Of California Methods for crystallographic structure determination employing hydrogen exchange analysis
ATE479760T1 (de) 2004-03-24 2010-09-15 Domantis Ltd Universelles signalpeptid gas1
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
CA2688434A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
CN102307897B (zh) * 2008-12-05 2016-01-20 葛兰素集团有限公司 选出蛋白酶抗性多肽的方法
WO2010081787A1 (en) 2009-01-14 2010-07-22 Domantis Limited IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
CN105061593B (zh) 2009-02-19 2018-08-03 葛兰素集团有限公司 改良的抗血清清蛋白结合变体
AR075505A1 (es) * 2009-02-19 2011-04-06 Glaxo Group Ltd Variantes de union a anti- albumina de suero mejoradas
WO2011006915A2 (en) * 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
KR20120092611A (ko) * 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
EP2603522A1 (en) * 2010-08-13 2013-06-19 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants

Similar Documents

Publication Publication Date Title
RU2577228C2 (ru) Анти-il-17-антитела, способ их получения и способ применения
JP2013529080A5 (enExample)
JP2016539096A5 (enExample)
JP2017520575A5 (enExample)
HRP20161043T1 (hr) Ljudska antitijela visokog afiniteta u odnosu na ljudski angiopoietin-2
RS66117B1 (sr) Poboljšana veziva serumskog albumina
FI2691417T4 (fi) Vasta-aineen Fc-variantteja
RS66173B1 (sr) Poboljšana veziva serumskog albumina
JP2010526028A5 (enExample)
JP2013537416A5 (enExample)
IL276286B2 (en) FC variants with improved binding to FCRN and extended half-life
ME00519B (me) Antitijela visokog afiniteta prema humanom il-6 receptoru
RU2019123112A (ru) Анти-il-5 антитела
IL266907B1 (en) Improved serum albumin binding immunoglobulin single variable domains
JP2013519721A5 (enExample)
CN104245736B (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
RU2017144098A (ru) Гетеродимеризованный полипептид
JP2016503412A5 (ja) Il−6アンタゴニストおよびその使用
JP2019506841A5 (enExample)
JP2009539349A5 (enExample)
JP2009519944A5 (enExample)
JP2014530001A5 (enExample)
JP2018509887A5 (enExample)
CA2930162A1 (en) Multifunctional antibodies binding to egfr and met
JP2016512214A5 (enExample)